Conclusion: At present, it is impossible to draw any firm conclusions about the effectiveness, or a lack of it, of smoking cessation competitions. This is due to a lack of well-designed comparative studies. Smoking cessation competitions have not been shown to enhance long-term cessation rates. The limited evidence suggesting that population-based Quit & Win contests at local and regional level might deliver quit rates above baseline community rates has not been tested adequately using rigorous study designs. It is also unclear whether the value or frequency of possible cash reward schedules influence the
PubMed 30784046 ↗Nicotine Patches
People mainly take Nicotine Patches for focus, mood. Based on 17 first-hand reports and 33 meta-analyses & systematic reviews in the medical literature. Ranked #294 of 1,974 overall.
Of reports that state an outcome, 61% are positive.
What Nicotine Patches does, according to users
Of the people who reported each effect, the share who said it got better.
3 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found.
Conclusion: There is limited evidence that either behavioural support or smoking cessation medication increases the proportion of young people that stop smoking in the long-term. Findings are most promising for group-based behavioural interventions, but evidence remains limited for all intervention types. There continues to be a need for well-designed, adequately powered, randomized controlled trials of interventions for this population of smokers.
PubMed 29148565 ↗Conclusion: Psychosocial interventions to support women to stop smoking in pregnancy can increase the proportion of women who stop smoking in late pregnancy and the proportion of infants born low birthweight. Counselling, feedback and incentives appear to be effective, however the characteristics and context of the interventions should be carefully considered. The effect of health education and social support is less clear. New trials have been published during the preparation of this review and will be included in the next update.
PubMed 28196405 ↗Conclusion: Study 1 demonstrated that a 21 mg/24-h patch was effective in reducing craving throughout the day, including the evening period when relapse risk is heightened. A further study comparing the 21 mg/24-h patch to a 15 mg/16-h nicotine patch found that craving was significantly lower at all times of day for smokers using the 21 mg/24-h patch. The studies were limited in that craving was only monitored for the first 2 weeks of quitting (when craving is most prominent), and cannot elucidate the impact of patch use on craving outside of this time. Also, there was substantial attrition of the sample
PubMed 18727842 ↗Dosage people report
As stated by users — not a recommendation. Follow the label or your doctor.
Reported side effects
How often each side effect came up across all reports.
What users say
Verbatim quotes, shortened only — each links to the original discussion.
“Patches don't hit me with a high, but I feel more focused, energized, and positive with them as opposed to no nicotine.”
“Substances, that trigger my reaction: Cerebrolysin, semax, selank, piracetam (but not phenylpiracitam), L-Carnitine and ALCAR, nicotine patches.”
“I've used nicotine patches for years and still have days where don't notice that I forgot to put one on”
“I find the patches to be most practical.”
“I like my patches, and the only reason I don't use them every day all year long is because it mildly suppresses my sex drive and because I am wary of mixing nicotine (by any route of delivery) and syrian rue or b. caapi.”
Other options for focus
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 2, 2026. How we rate